Design
Review
Supports randomized trials of combination antithrombotic regimens in atherosclerosis; leaves open any role in clinical practice.
Atherosclerosis is a highly prevalent disorder and remains a leading cause of morbidity and mortality in the United States. Recent advances in vascular biology have led to a better understanding of the mechanisms underlying atherogenesis. The central role played by plaque disruption, and by adhesion, activation, and aggregation of platelets that trigger activation of the coagulation cascade in the pathogenesis of acute thrombotic events is also better understood. Combination antithrombotic therapy targeting various platelet activation mechanisms and the coagulation cascade may help optimize the management of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Peter Libby (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: